[Metabolic syndrome, type 1 diabetes mellitus and insulin resistance].
Although metabolic syndrome is generally associated with type 2 diabetes mellitus, the present review emphasizes the possible presence of metabolic syndrome in type 1 diabetes and the impact of insulin resistance on micro- and macrovascular complications. Results of major intervention studies in type 1 diabetes have led to a generalized intensive insulin treatment, being an excessive weight gain one of the consequences. Since abdominal obesity and hyperglycemia are 2 components of the metabolic syndrome, an increase in the percentage of metabolic syndrome in patients with type 1 diabetes is not surprising, though its prevalence does not reach that reported for type 2 diabetes. For insulin sensitivity quantification in patients with type 1 diabetes the estimated glucose disposal rate (eGDR): it consists of calculating a score based on clinical factors of the patient, which shows an inverse relationship with the development of micro- and macrovascular complications. Moreover, insulin-resistance identification in type 1 diabetes may have therapeutic implications.
Chillarón
Juan José
JJ
Servicio de Endocrinología, Hospital del Mar, Barcelona, España.
Goday
Albert
A
Pedro-Botet
Juan
J
D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D024821:Metabolic Syndrome / Q000453:epidemiology* / Q000503:physiopathology*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone